Infectious Disease Assay Development Core

项目总结 传染病检测发展实验室(IDAD)用于研究传染病的化学生物学 疾病提供了小分子文库的分析开发和筛选方面的专业知识。这些化合物 从屏幕上识别的用作解剖作用机制的化学工具或探针 调整传染病目标。除了物质和技术资源的可用性外， 进行化学筛选，关键是设计、开发和优化真正反映特定情况的分析方法 传染病生物学中的靶标作用。堪萨斯大学已经建立了成功的HTS 拥有优秀的智力和体力资源。传染病检测的发展核心 在CBID Funding的第一阶段建立，利用这些资产并扩展现有能力 通过提供额外的专业知识和专门的研究空间来开发针对新疾病的检测方法 相关目标。此核心的总体目标是提供全方位的专业知识、设施、服务和 在HTS化验设计、开发、验证、小规模和大规模筛查方面的培训 以生物体(细胞)为基础的或生化传染病目标。这些努力的预期结果是 适用于可进行自动化大规模筛查的小型化和经验证的分析 内部或外部。预计专业知识和资源也将使调查人员能够 对发现化学探测器的资助机会公告作出回应的竞争性建议或 来自国防部或NIH的治疗剂。此外，通过成功生成的命中 化验开发和小分子筛选工作是计算的起点 化学生物学与合成化学生物学核心的成功开发优化 用作化学探针和传染病治疗前药物的化合物。

PROJECT SUMMARY The Infectious Disease Assay Development (IDAD) laboratory for studying the Chemical Biology of Infectious Disease provides expertise on assay development and screening of small molecule libraries. The compounds identified from the screen serve as chemical tools or probes for dissecting mechanism of action and modulating infectious disease targets. In addition to the availability of physical and technical resources to perform chemical screening, it is critical to design, develop and optimize assays that truly reflect specific target function in infectious disease biology. The University of Kansas has an established and successful HTS facility with excellent intellectual and physical resources. The Infectious Disease Assay Development core established in Phase I of CBID funding takes advantage of these assets and expands the current capabilities by providing additional expertise and dedicated research space to develop assays against novel disease relevant targets. The overall goal of this core is to provide a full array of expertise, facilities, services, and training in the area of HTS assay design, development, validation, small and large-scale screening for organism (cell) based or biochemical infectious disease targets. The expected outcomes of these efforts are miniaturized and validated assays suitable for automated large-scale screening that can be performed internally or externally. The expertise and resources are also expected to enable investigators to develop competitive proposals in response to funding opportunity announcements for discovery of chemical probes or therapeutic agents from Department of Defense, or NIH. Additionally, hits generated through successful assay development and small molecule screening efforts serve as starting points for the Computational Chemical Biology and the Synthetic Chemical Biology cores for successful development of optimized compounds for use as chemical probes and pre-therapeutics for infectious diseases.